Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Satya Garimella

Clinical Cardiac Electrophysiology Jeffersonville, IN Medical Doctor

NPI 1164452850 CMS profile 98258

41 Quatermaster Court, Jeffersonville, IN 47130

Open in the dashboard

General payments

$19,586

278 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$37,285 paid to institutions, not to them · program years 2021–2024

Through program year 2025, Satya Garimella of Jeffersonville, IN is reported in the CMS Open Payments database as having received $19,586 across 278 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $37,285 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 51st percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,676 36
2024 General $4,157 63
2023 General $5,210 48
2022 General $1,742 21
2021 General $1,578 17
2020 General $803 16
2019 General $4,420 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Satya Garimella
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Satya Garimella were reported at $1,676. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Satya Garimella Clinical Cardiac Electrophysiology median Middle half National median
2019 $4,420 $2,361 $585–$8,260 $163
2020 $803 $993 $247–$4,351 $114
2021 $1,578 $1,185 $326–$4,739 $132
2022 $1,742 $2,073 $554–$6,789 $149
2023 $5,210 $2,568 $759–$8,159 $160
2024 $4,157 $2,557 $703–$7,403 $164
2025 $1,676 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $6,794 76 payments
  2. Abbott Laboratories $4,235 41 payments
  3. Medtronic, Inc. $1,679 16 payments
  4. Medical Device Business Services, Inc. $1,578 8 payments
  5. Biosense Webster, Inc. $792 10 payments
  6. Inari Medical, Inc. $642 9 payments
  7. Abiomed $472 4 payments
  8. E.R. Squibb & Sons, L.L.C. $439 26 payments
  9. Atricure, Inc. $341 4 payments
  10. AstraZeneca Pharmaceuticals LP $274 4 payments
  11. Other $2,340 80 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,503 242 payments
  2. Travel and Lodging $8,049 34 payments
  3. Education $34 2 payments
Products named General payments · program years 2019–2025
  1. AVEIR Cardiac Rhythm Management $2,068 12 payments
  2. Carto 3 System $1,602 10 payments
  3. RHYTHMIA $1,058 13 payments
  4. AVEIR Structural Heart $869 4 payments
  5. FLOWTRIEVER CATHETER, S $832 10 payments
  6. Carto 3 $575 6 payments
  7. CT THROMBECTOMY SYSTEM KIT $452 8 payments
  8. AMPLATZER AMULET $441 4 payments
  9. WATCHMAN Access System $437 10 payments
  10. WATCHMAN $325 4 payments
  11. Other $7,963 192 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

4,521

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$930,916

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

32.9%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 539 $530,551
Xarelto Rivaroxaban Brand 168 $177,052
Multaq Dronedarone Hcl Brand 40 $58,149
Entresto Sacubitril/Valsartan Brand 34 $55,007
Farxiga Dapagliflozin Propanediol Brand 30 $32,636
Dofetilide Generic 161 $28,606
Metoprolol Succinate Generic 572 $6,101
Amiodarone Hcl Generic 106 $4,866
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 150 $3,540
Flecainide Acetate Generic 43 $3,441

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$289,866

Medicare's payments for the services billed

Medicare patients

1,054

Average age 76

Services billed

5,307

527 women, 527 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 61%
Atrial fibrillation 61%
Arthritis 60%
Heart failure 46%
Diabetes 44%
Chronic kidney disease 42%
COPD 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $101
$101 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $40
$40 168 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $38
$38 — —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $35
$35 40 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $32
$32 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

278 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record